Cohance Lifesciences Ltd. (COHANCE) fundamentals
Cohance Lifesciences Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as COHANCE (ISIN INE03QK01018). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Cohance Lifesciences Ltd. does
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
Valuation and market data
| Last close | ₹440.20 |
|---|---|
| Market capitalisation | ₹14,090 crore |
| Enterprise value | ₹15,091 crore |
| P/E (TTM) | 93.86 |
| Price to book | 3.49 |
| Price to sales (TTM) | 3.68 |
| Book value per share | ₹126.02 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Mar 09 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,075 crore | ₹314 crore | ₹229 crore | 5.98 |
| Mar 2025 | ₹2,569 crore | ₹650 crore | ₹491 crore | 12.89 |
| Mar 2024 | ₹1,108 crore | ₹400 crore | ₹296 crore | 11.65 |
| Mar 2023 | ₹1,375 crore | ₹579 crore | ₹433 crore | 16.99 |
| Mar 2022 | ₹1,508 crore | ₹722 crore | ₹558 crore | 21.92 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 57.5% |
|---|---|
| Foreign institutions (FII) | 6.5% |
| Mutual funds | 18.2% |
| Other domestic institutions | 1.9% |
| Retail and others | 15.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.